This article is more than 5 years old. Information may no longer be current.

Novartis announces Alcon Q3 net sales of $2.7 billion

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alcon’s earnings for the third quarter of 2014 included a 5% increase in net sales to $2.7 billion, with strong growth in surgical and moderate growth in vision care and ophthalmic pharmaceuticals, according to a press release from Novartis.

An 8% increase in surgical growth was attributed primarily to strong sales for the Centurion phacoemulsification cataract platform and the LenSx femtosecond laser platform.

Operating income increased by 52% to $381 million, which was driven by strong operating performance and the ending of integration charges in 2013, according to the release.

Alcon also saw a 10% increase in core operating income to $960 million due to higher sales and lower functional costs that resulted from productivity programs.

Novartis reported Q3 net sales of $14.7 billion, marking a 4% increase from the previous year, as well as a 14% operating income growth to $3 billion. Continuing operations grew 2% to $13 billion, and pharmaceutical net sales were reported at $7.9 billion, according to the release.